A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian Neoplasms|Breast Neoplasms|Prostatic Neoplasms
Interventions: BIOLOGICAL: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)